Sign In
Buy PSNL
$10.78
-0.360 (-3.23%)
At Close: Jun 03, 2026
Personalis to Announce Second Quarter 2025 Financial Results
04:01pm, Tuesday, 22'nd Jul 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2025 financial results on Tuesday,
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 18'th Jul 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors grant
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
04:00pm, Wednesday, 09'th Jul 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication,
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
08:11am, Thursday, 03'rd Jul 2025
Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the
Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?
11:41am, Tuesday, 17'th Jun 2025
Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength
Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
04:00pm, Tuesday, 03'rd Jun 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
04:00pm, Monday, 02'nd Jun 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCA
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
06:00am, Thursday, 22'nd May 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (
Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
04:01pm, Wednesday, 14'th May 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Craig-Hallum 22n
Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript
08:41pm, Tuesday, 06'th May 2025
Personalis, Inc. (NASDAQ:PSNL ) Q1 2025 Earnings Conference Call May 6, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and Preside
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
07:00pm, Tuesday, 06'th May 2025
Personalis (PSNL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.26 per share a year ago.
Personalis Reports First Quarter 2025 Financial Results
04:01pm, Tuesday, 06'th May 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31,
Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
05:00pm, Monday, 28'th Apr 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced new interim analysis results of the VICTORI study showing stron
Hanover Insurance Set to Report Q1 Earnings: What to Expect
02:20pm, Monday, 28'th Apr 2025
THG's Q1 results are likely to reflect a reduction in Personal Lines policy count in the Midwest and the implementation of deductibles in most of Personal Lines.
Personalis to Announce First Quarter 2025 Financial Results
04:01pm, Tuesday, 22'nd Apr 2025
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2025 financial results on Tuesday, M
